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Abstract
Background: The sustained virological response to interferon-alpha (IFN-a) in individuals infected with hepatitis C
virus (HCV) genotype 1 is only 50%, but is about 80% in patients infected with genotype 2-6 viruses. The molecular
mechanisms explaining the differences in IFN-a responsiveness between HCV 1 and other genotypes have not
been elucidated.
Results: Virus and host cellular factors contributing to IFN responsiveness were analyzed using a green
fluorescence protein (GFP) based replication system of HCV 2a and Huh-7 cell clones that either possesses or lack a
functional Jak-Stat pathway. The GFP gene was inserted into the C-terminal non-structural protein 5A of HCV 2a
full-length and sub-genomic clones. Both HCV clones replicated to a high level in Huh-7 cells and could be
visualized by either fluorescence microscopy or flow cytometric analysis. Huh-7 cells transfected with the GFP
tagged HCV 2a genome produced infectious virus particles and the replication of fluorescence virus particles was
demonstrated in naïve Huh-7.5 cells after infection. IFN-a effectively inhibited the replication of full-length as well
as sub-genomic HCV 2a clones in Huh-7 cells with a functional Jak-Stat pathway. However, the antiviral effect of
IFN-a against HCV 2a virus was not observed in Huh-7 cell clones with a defect in Jak-Stat signaling. HCV infection
or replication did not alter IFN-a induced Stat phosphorylation or ISRE promoter-luciferase activity in both the
sensitive and resistant Huh-7 cell clones.
Conclusions: The cellular Jak-Stat pathway is critical for a successful IFN-a antiviral response against HCV 2a. HCV
infection or replication did not alter signaling by the Jak-Stat pathway. GFP labeled JFH1 2a replicon based stable
cell lines with IFN sensitive and IFN resistant phenotypes can be used to develop new strategies to overcome IFN-
resistance against hepatitis C.
Background
Hepatitis C virus (HCV) is the most common blood-
borne infection affecting the liver. Chronic HCV infec-
tion often leads to the development of liver cirrhosis
and cancer [1]. HCV infection often does not present
early symptoms and thus can go undetected while sig-
nificant liver damage sets in over the course of 10-20
years. There are 180 million people currently infected
with HCV worldwide [2,3]. The incidence of new HCV
infection is increasing each year, creating a significant
public health problem. The standard treatment for
chronic HCV infection is interferon with ribavirin, but
many patients infected with certain viral strains develop
resistance to treatment [4,5]. The mechanisms of inter-
feron action and resistance in chronic HCV infection
are currently not well understood. Development of effi-
cient HCV cell culture systems for all major HCV
strains is required to understand the role of host-virus
interaction in the IFN-antiviral response.
HCV, a member of the Flaviviridae,i sa ne n v e l o p e d
virus containing a single-stranded positive sense RNA
genome approximately 9600 nucleotides in length [6,7].
The nucleotide sequences of HCV genomes isolated in
different parts of world vary considerably and are quite
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numerous sub-types of HCV that have been described
from all over the world [8-10]. Genotype 1 (subtype 1a
and 1b) is the most common in the United States, fol-
lowed by genotype 2 and 3 [10,3]. Genotype 3 is most
common in the Indian subcontinent [8]. Genotype 4 is
the most common genotype in Africa and the Middle
East [11]. Genotypes 5 and 6 are most common and
predominant in South Africa and Southeast Asia [12].
In spite of high sequence variability among different
HCV genotypes, the genomic organization of all HCV
strains starts with a highly conserved untranslated
sequences (called 5’ U T R ) ,f o l l o w e db yal a r g eo p e n
reading frame, and terminating with 3’-untranslated
sequences. The large polyprotein is processed by cellular
and viral proteases into structural proteins (core, E1,
and E2) and nonstructural proteins (p7, NS2, NS3,
NS4A, NS4B, NS5A, and NS5B). The nonstructural pro-
teins NS3 to NS5B are essential for RNA replication
and have distinct functions in the HCV life cycle. The 5’
and 3’ UTR sequences of HCV contain numerous cis-
acting signals that are absolutely required for RNA
translation and replication as shown by in vitro experi-
ments using the cell culture system. Despite the high
nucleotide sequence homology of the 5’ and 3’ UTRs
among all genotypes of HCV, the efficiency of RNA
genome replication of different HCV strains in the cell
culture varies significantly [13]. Some strains of HCV
with adaptive mutations replicate efficiently in the cell
culture, whereas others do not require any adaptive
mutations. The best example is the JFH1 clone of HCV
2a strain that replicates to a higher level in cell culture
and generates more infectious virus particles compared
to all other full-length infectious clones [14-16]. These
observations suggest that HCV genetics and host cellu-
lar environments are the two major determinants of the
efficacy of HCV replication and its response to antiviral
therapy.
Interferon alpha (IFN-a) along with ribavirin has been
widely used as a standard treatment option for patients
with chronic HCV infection all over the world [3]. How-
ever, the sustained virological response to IFN-a in indi-
viduals infected with HCV genotype 1 is only 50% as
compared with 80% in patients infected with genotype 2
to 6 viruses [17]. Molecular mechanisms explaining why
certain genotype viruses respond better to IFN-a than
others have not been elucidated. We have shown that
IFN-a effectively inhibits the IRES mediated translation
of all HCV strains in the cell culture, indicating that dif-
ferential resistance is not due to IRES sequence hetero-
geneity [18-20]. To gain an insight into the mechanisms
of IFN resistance in the HCV cell culture model, we
have developed Huh-7 cell lines in which the HCV 1b
Con1 strain is resistant to IFN, after prolonged IFN-a
treatment of a low inducer Huh-7 replicon cell line
[21,22]. We demonstrated that phosphorylation of Stat1
and Stat2 proteins in the IFN-resistant replicon cell
lines is blocked due to reduced phosphorylation of Jak1
and Tyk2 proteins [21,22]. These studies provided direct
evidence that a defective Jak-Stat pathway makes HCV
replication resistant to interferon treatment in a replicon
cell line, and indicated that cellular factors are impor-
tant for determining the response of HCV to IFN-a
treatment. To extend our observations, we have exam-
ined the replication and anti-viral response of an IFN-
sensitive HCV 2a virus clone in a Huh-7 clone with a
defective Jak-Stat pathway. For this purpose, we first
developed a chimeric clone between GFP and a highly
efficient HCV 2a virus. Insertion of the GFP coding
sequences into HCV 2a allowed us to study a high level
replication of the virus in Huh-7 cells directly by fluor-
escence microscopy or flow cytometric analysis. We also
determined that replication of HCV 2a can only be
inhibited by IFN-a i nad o s ed e p e n d e n tm a n n e ri n
Huh-7 cells with a functional Jak-Stat pathway. Replica-
tion of the full-length and sub-genomic clone of a HCV
2a strain was not inhibited by IFN-a in Huh-7 cell
clones with a defective Jak-Stat pathway. Infection with
full-length virus or stable replication of sub-genomic
HCV RNA did not alter the state of Jak-Stat signaling
or interferon sensitivity in these two different Huh-7
c l o n e s .W eh a v en o wd e v e l o p e dm u l t i p l eG F Pt a g g e d
HCV sub-genomic replicon cell clones in which replica-
tion of HCV are totally resistant to IFN-a. We believe
that these cell clones can be used to understand the cel-
lular basis of IFN-resistance in a cell culture as well as
develop alternative strategies to overcome mechanisms
of resistance.
Materials and methods
Cell culture
Huh-7.5 cells, obtained from the laboratory of Dr.
Charles M. Rice (Center for the Study of Hepatitis C,
The Rockefeller University, New York), were cultured at
37°C in Dulbecco’s modified Eagle’s medium supple-
mented with 2 mM l-glutamine, nonessential amino
acids, 100 U/ml of penicillin, 100 μg/ml of streptomycin
and 10% fetal bovine serum, under 5% CO2 conditions.
Interferon resistant (R-24/1) replicon cells were gener-
ated in our laboratory by prolonged treatment of low
inducer replicon cell lines (Con-15, Con-17, and Con-
24) with IFN-a as described previously [21,22]. A cured
Huh-7 cell line with defective Jak-Stat pathway (R-Huh-
7) was prepared from IFN-a resistant replicon cell line
(R-24/1) after repeated treatment with cyclosporine-A
(1 μg/ml) as described previously [22]. Interferon sensi-
tive cured Huh-7 cells (S-Huh-7) were derived from the
5-15 replicon cell line after treatment with IFN-a.
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in the cured S-Huh-7 and R-Huh7 cells were examined
by measuring their ability to activate the ISRE-luciferase
promoter in the presence of exogenous IFN-a.T h e
expression of functional Jak-Stat signaling proteins in
these cells after IFN-a treatment was examined by wes-
tern blot analysis of phosphorylated Stat1 and Stat2. All
the resistant cell lines have defects in the phosphoryla-
tion of Stat1 and Stat2 protein, whereas the S-Huh-7
clone showed a high level of phosphorylation of Stat1
and Stat2 proteins within 30 minutes of IFN-a treat-
ment [22]. All Huh-7 cell lines were maintained in Dul-
becco’s modified Eagle’s medium supplemented with 2
mM l-glutamine, nonessential amino acids, 100 U/ml of
penicillin, 100 μg/ml of streptomycin and 5% fetal
bovine serum.
Construction of full-length and sub-genomic JFH1 2a
chimeric clones
The JFH1 full-length cDNA clone of HCV 2a strain
which was isolated from a chronically infected Japanese
fulminant hepatitis patient was obtained from Wakita
and his coworkers [14]. Chimeric clones between JFH1
and enhanced green fluorescent protein (EGFP) were
constructed in our laboratory by the standard overlap-
ping PCR amplification and cloning methods. The coding
sequence of GFP was amplified from pEGFP-N1 plasmid
and inserted in-frame of the NS5A coding sequence of
the JFH1 cDNA clone between 2394 and 2395 amino
acids position (between 417 and 418 amino acids of the
NS5A protein). The PCR amplification of recombinant
DNA and cloning was performed in four different steps.
In the first step, the 228 bp (F1) recombinant DNA frag-
ment containing 70 amino acids of NS5A (nts.7339-
7546) fusion with the first 6 amino acids of EGFP-N1
was amplified using a sense primer (S/7336-7360/HCV-
5’-CCTCCCCCAAGGAGACGCCGGACA-3’)a n da n t i -
sense primer (AS/7529/HCV- 5’CTCGCCCTTGCTCAC-
CATG GGGGGCATAGAGGAGGC-3’). In the second
step, the 719 bp (F2) recombinant DNA fragment con-
taining the total EGFP-N1 open reading frame (ORF)
fused with the N- and C-termini of HCV NS5A was
amplified using sense and anti-sense overlapping primers
(S/7529/GFP- 5’-GCCTCCTCTATGCCCCCCATGGT-
GAGC AAGGGCGAG-3’ and (AS/7547-7564/GFP 5’-
TCCAGGCTCCCCCTCGAGCTTGTACA
GCTCGTCCAT-3’). In the third step, the recombinant
531 bp DNA fragment (F3) containing last 6 amino acids
of EGFP-N1 and 177 amino acids of NS5A (nt. 7547-
8077) was amplified by using sense primers (S/7547/
HCV- 5’-ATGGACGAGCTGTACAAG CTCGAGGGG-
GAGCCTGGA-3’) and anti-sense primer (AS/8059-
8077/HCV-5’-GTCTTCCAGGAGGTCCTTCCACAC-
3’). In fourth step, the F1, F2 and F3 PCR fragments were
assembled into the 1478 bp DNA fragment through over-
lapping PCR. In the final step, the recombinant DNA was
digested with restriction enzyme RsrII and HpaI, gel puri-
fied and then ligated with pJFH1 clone using the unique
RsrII and HpaI restriction sites present in the NS5A
gene. The resulting plasmid was named pJFH1-GFP. The
recombinant plasmid was amplified and the construction
was confirmed by sequence analysis. A full-length
pJFH1-GFP plasmid clone was prepared with a GDD to
GND mutation in the NS5B gene to use as a control
(pJFH1-GND-GFP) in the replication assay. A full-length
pJFH1-GFP plasmid was also prepared with a deletion in
the E1-E2 gene (pJFH1-ΔE1E2-GFP) to use as a control
i nt h ei n f e c t i v i t ya s s a y .T og e n e r a t eas u bg e n o m i cG F P
replicon clone of HCV 2a, the recombinant plasmid con-
taining the NS5A and EGFP-fusion was excised from
full-length pJFH1-GFP plasmid using the NsiI and HpaI
enzyme and re-cloned into the pSGR replicon [23]. This
chimeric clone was named pSGR-GFP. As a control, we
created a mutant construct pSGR-GND-GFP clone with
a point mutation that changes a GDD motif to GND,
abolishing the RNA polymerase activity of the NS5B pro-
tein. All the recombinant plasmids constructs were con-
firmed by DNA sequence analysis.
In-vitro RNA synthesis
Full-length (pJFH1-GFP) and sub-genomic replicon
(pSGR-GFP) plasmids were linearized with XbaI restric-
tion enzyme and purified by phenol chloroform extrac-
tion and precipitated by ethanol. The HCV full length
and sub-genomic RNAs were transcribed from XbaI lin-
earized plasmid DNA templates using the MEGA-script
T 7k i t( A m b i o n ,A u s t i n ,T X ,U S A ) .In vitro transcribed
RNA was treated with DNase I to eliminate any residual
plasmid DNA, extracted with phenol and chloroform,
and then precipitated with absolute ethanol. The RNA
pellet was re-suspended in nuclease free water and 10
μg aliquots of this RNA were stored at -80°C. The integ-
rity of in vitro transcribed RNA was verified by agarose
gel electrophoresis.
RNA transfection
Huh-7.5, S-Huh-7 and R-Huh-7 cells were electropo-
rated with in vitro transcribed HCV RNA using a stan-
dard protocol described previously [17]. Briefly, cells
were harvested using trypsin-EDTA, pelleted by centri-
fugation and washed in 10 ml of phosphate buffered sal-
ine (PBS). The cell pellet was suspended in PBS (10
7
cells per ml). Ten micrograms of in vitro transcribed
RNA was mixed with 400 μl of Huh-7 cell suspension
in a cuvette (0.4 cm, Bio-Rad) and subjected to an elec-
tric pulse at 960 μF and 270 volts using a gene pulser
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were diluted in 10 ml of complete medium and plated
in a 100-mm diameter cell culture dish.
Replication assay
To study replication of full-length HCV-GFP chimeric
RNA, the electroporated Huh-7 cells were cultured in a
100-mm plate with regular growth medium. The expres-
sion of GFP in the transfected Huh-7 cells was recorded
at 0, 24, 48, 72 and 96 hours post-transfection. To study
the replication of HCV sub-genomic RNA, stable Huh-7
cells replicating sub-genomic RNA were prepared.
Cured Huh-7 cells derived from interferon sensitive (S-
Huh-7) and resistant replicon cell lines (R-Huh-7) in
our laboratory were used. Huh-7 cells electroporated
with sub-genomic RNA were cultured in a growth med-
ium supplemented with 500 μg/ml G-418 drug. These
cells were maintained with a regular medium change at
every three days for 3-4 weeks until distinct G-418 resis-
tant cell colonies were developed. To make a stable cell
line replicating HCV 2a sub-genomic RNA, multiple G-
418 resistant cell clones were isolated and cultured in
medium supplemented with 1 mg/ml G-418. In these
stable cell lines absence of HCV plasmid DNA integra-
tion was confirmed by direct PCR followed by Southern
blot analysis for the neo gene (sense 5’-ATCGAATT-
CATCGTGGCTGGCCA-3’;a n t i - s e n s e5 ’-CTA-
GAATTCGGCGCGAGCCCCTG-3’;p r o b e5 ’-
GCTTGGTGGTCGAATGGGCAG GTAGCCGGA-3’.
Infectivity assay
An infectivity assay for HCV was performed using a
published protocol [15]. Huh-7.5 cells were transfected
with 20 μgo fin vitro transcribed full-length JFH1-GFP
RNA by electroporation method. After 72 h, cells were
collected by scraping and then lysed by four rounds of
freeze-thaw cycles. The cell lysates were clarified by cen-
trifugation at 3400 rpm for five minutes. The clear
supernatant was collected and the titer of HCV in the
supernatant was determined by real-time RT-PCR using
a primer set targeted to the 5’UTR. A tissue culture
infective dose (TCID50) was determined using 10-fold
serial dilution of the virus containing supernatant on 2-
well Lab-Tek chamber slides (Nalge Nunc International,
Rochester, New York). Briefly, Huh-7.5, S-Huh-7 and R-
Huh-7 cells were seeded on a 2-well glass chamber slide
at a density of 1 × 10
4 cells per well. The next day, the
culture medium was removed and 1-ml of serial dilu-
tions of culture supernatant containing infectious virus
was added to the wells. The cells were incubated over-
night at 37°C. On the following day the culture medium
was removed, and the cells were washed once using PBS
and then incubated in fresh complete medium. After 96
hours post-transfection, the cells were removed, washed
in PBS, fixed in 4%-parformaldehyde for 30 minutes and
then counter stained with Hoechst dye (H33342, Calbio-
chem, Darmstadt, Germany) for 15 minutes at 37°C.
Cells were examined at 484 nm using a fluorescence
microscope (Olympus) for expression of green fluores-
cence. Cells were then examined at 340 nm for blue
nuclear staining. For each area, two sets of pictures
were taken. The final image was generated by superim-
posing blue nuclear fluorescence of Hoechst dye with
green fluorescence of GFP using Abode Photoshop soft-
ware (V 7.0). The numbers of green positive cells in ten
different fields were counted and the percentage of
green fluorescence positive cells in the culture was
determined. The dilution of virus-containing superna-
tant that showed 50% GFP positive cells 96 hours after
infection in the culture (called the TCID50) was deter-
mined. The MOI of the infectious culture supernatants
was determined by dividing the TCID50 with the cell
number used in the infectivity assay.
Interferon treatment
To study the effect of interferon on the full-length HCV
2a clone, transfected or infected Huh-7 cells were trea-
ted with increasing concentrations of IFN-a(Intron A,
Schering-Plough, NJ, USA). The antiviral effect of IFN-a
against HCV using different Huh-7 clones was con-
firmed by observing GFP expression under a fluores-
c e n c em i c r o s c o p eo rb yf l o wc y t o m e t r i ca n a l y s i s ,a n d
HCV RNA levels was measured by RPA.
Ribonuclease protection assay (RPA)
Total RNA was prepared from the cell pellet by the
GITC method and subjected to RPA for the detection of
genomic positive-strand HCV RNA. For RPA experi-
ments, 25 μg of the total RNA was mixed with a nega-
tive-strand RNA probe targeted to the 5’UTR of HCV
(1 × 10
6 cpm) in a 10 μl hybridization solution, dena-
tured for 3 minutes at 95°C and then hybridized over-
night at 50°C. RNase digestion was performed in 200 μl
of RNase digestion buffer (10 mM Tris, pH 7.5, 5 mM
EDTA and 0.3 M NaCl) containing RNaseA/T1 cocktail
at 1:100 dilutions (Ambion Inc., Austin, TX) for an hour
at 37°C. Then the sample was treated with 2.5 μl of 25%
SDS and 10 μl of proteinase K (20 mg/ml) for 15 min-
utes. Samples were extracted with phenol and chloro-
form and then precipitated after addition of 2.5 volumes
of absolute ethanol. The pellet was obtained by centrifu-
gation for 30 minutes at 12,000 rpm. The RNA pellet
was washed with 70% ethanol, suspended in 8 μlo fg e l
loading buffer, boiled for one minute and separated on a
6% polyacrylamide TBE-Urea gel (Invitrogen, Carlsbad,
CA). The gel was dried and exposed to X-ray film
(Kodak Biomax-XAR, Rochester, NY). We prepared a
plasmid construct called pCR-II (2a), which contained
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JFH1 clone (pCR-II NT-218) (Invitrogen). This plasmid
was linearized with HindIII restriction enzyme and a
positive strand RNA probe was prepared using T7 RNA
polymerase in the presence of 32p labeled CTP. Like-
wise, this plasmid was linearized with XbaI restriction
enzyme and Sp6 RNA polymerase was used to prepare a
negative strand RNA probe for the detection of a posi-
tive strand HCV RNA. The same amounts of the RNA
extracts were subjected to RPA for GAPDH mRNA. We
used a linearized pTRI-GAPDH-human anti-sense con-
trol template to prepare a probe to detect GAPDH
mRNA using Sp6 RNA polymerase (Ambion Inc., Aus-
tin, TX). The appearance of 218 (HCV 2a) and 317 nts
protected fragments indicated the presence of the HCV
positive-strand and the GAPDH mRNA, respectively.
Flow analysis
The percentage of Huh-7 cells expressing GFP after
transfection with full-length GFP-RNA transfected cells
was analyzed by flow cytometric analysis. Cells were
transfected with 10 μgo fin vitro transcribed RNA in 6-
well plates, and harvested by treatment with trypsin-
EDTA at 24, 48, 72 and 96 hours post-transfection. The
cells were pelleted by centrifugation at 500 rpm in a
refrigerated centrifuge. The cell pellet was resuspended
in 4% paraformaldehyde for 30 minutes, and washed
twice in 10 ml of PBS using centrifugation. After this
step, the cell pellet was resuspended in 1 ml of PBS and
analyzed by flow cytometer (BD-Biosciences). The per-
centage of GFP expressing cells in the replicon culture
was determined by flow analysis using the identical pro-
cedure. Stable replicon cells after interferon treatment
were harvested by trypsin-EDTA treatment and analyzed
by flow cytometry.
Real-time RT-PCR
Real time RT-PCR was performed to quantify HCV
RNA levels in the infected cell culture using a published
protocol [24]. The 243 bp HCV DNA was amplified
from the RNA extract by reverse transcription polymer-
ase chain reaction using the outer sense (OS) primer 5’-
GCAGAAAGCGCCTAGCCATGGCGT-3’ (67-90) and
outer anti-sense (OAS) primer 5’-CTCGCAAGCGCCC-
TATCAGGCAGT-3’ (287-310). First the complementary
DNA synthesis was performed from positive strand
HCV-RNA using an outer anti-sense primer (OAS) tar-
geted to the highly conserved 5’UTR region of HCV in
20 μl volume. Briefly, 2 μgm of total cellular RNA were
mixed with 1 μl OAS primer (200 ng/μl), denaturized at
65°C for 10 minutes and annealed at room temperature.
Avian myeloblastosis virus (AMV) reverse transcriptase
(10 U) (Promega, Madison, WI) was added and incu-
bated at 42°C for 60 minutes in the presence of 50
mmol/L Tris, pH 8.3, 50 mmol/L ethylenediaminetetraa-
cetic acid (EDTA), 500 nmol/L dNTP, 250 nmol/L sper-
m i d i n e ,a n d4 0UR N a s i n( P r o m e g a ) .T h ec D N Aw a s
stored at -20°C until use. SYBR Green real time PCR
amplification was performed in 20 μl of volume contain-
ing 10 μl of SYBR Green ER qPCR SuperMix, 1 μl (250
ng/ul) of sense and antisense primer with 4 μlo fc D N A
and 4 μl of distilled water. All samples were run in tri-
plicate. The amplification was carried out using the
standard program recommended by Bio-Rad Laboratory
that includes: 50°C for 2 minutes, 95°C for 8 minutes,
then additional 50 cycles wherein each cycle consists of
a denaturation step at 95°C for 10 seconds, and anneal-
ing and extension step at 60°C for 30 seconds. At the
end of the amplification cycles, melting temperature
analysis was performed by a slow increase in tempera-
ture (0.1°C/s) up to 95°C. Amplification, data acquisi-
tion, and analysis were performed on CFX96 Real Time
instrument (Bio Rad) using CFX manager software (Bio
Rad).
Results
High-level replication of pJFH1-GFP chimera clone in
Huh-7.5 cells
Replication of the full-length HCV 2a genome is possi-
ble due to the availability of the JFH1 cDNA clone.
H o w e v e r ,t h eh i g h l ys e n s i tive RT-PCR and immunode-
tection methods are most often needed to detect repli-
cation of HCV in the transfected cells. To overcome the
technical difficulties associated with the detection of the
full-length viral RNA replication, we constructed chi-
meric clones of the JFH1 clone and GFP so that replica-
tion of whole viral genome in the transfected cells could
be examined by fluorescence microscopy. Previous
reports suggest that heterologous sequences can be
inserted into the HCV genome without altering its abil-
ity to replicate [25-28]. The coding sequence of GFP
was inserted into C-terminus of the NS5A protein of
HCV at the 2394 amino acid position. Chimeric clones
of GFP and full-length, and a sub-genomic replicon of
HCV 2a were prepared (Fig. 1). The N-terminal and C-
terminal fusion of HCV NS5A with EGFP protein was
confirmed by sequence analysis. To study the replication
of full-length virus, in vitro transcribed RNA derived
from wild type and GND-mutant clone were electropo-
rated into Huh-7.5 cells. The expression of GFP was
recorded in a kinetic study. The replication of full-
length JFH1-GFP chimera in the transfected Huh-7.5
cells was seen as early as 24 hour post-transfection and
the number of GFP positive cells in the culture
increased gradually at 48, 72 and 96 hours (Fig 2A). In
contrast, replication of the JFH1-GND-GFP mutant
RNA in Huh-7.5 cells was not observed at 48, 72 or 96
h o u r sp o s t - t r a n s f e c t i o n ,w h i l eo n l yav e r yf a i n tG F P
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fection (Fig. 2B). The efficiency of replication of chi-
meric clones in Huh-7.5 cells after RNA transfection
was observed in approximately 8% of cells as examined
by flow cytometry (Fig. 2C and 2D). Replication of full-
length JFH1-GFP chimera clone was confirmed by
examining HCV positive and negative strand RNA levels
by RPA assay. The levels of HCV RNA in the full-length
transfected cells and GND mutant transfected cells were
clearly different (Fig 3A). As expected, the levels of
mutant RNA dropped below the input level and
remained undetected at 48, 72 and 96 hours post-trans-
fection. The level of HCV positive strand RNA seen in
the RPA assay appeared to be higher at an earlier time
point in the full-length transfected cells at a later time
point. This may be due to an input RNA carryover dur-
ing the transfection step. There was a good correlation
between the amount of HCV RNA and expression of
GFP at later time points.
HCV is a positive strand RNA virus that replicates via
the synthesis of negative strand RNA. To demonstrate
that the replication of transfected RNA resulted in the
production of negative strand RNA in the transfected
cells, RPA for negative strand HCV RNA was performed
in the transfected cells at 0, 24, 48, 72 and 96 hours
post-transfection. Negative strand HCV RNA was not
detectable at the zero-time point but appeared at 24
Figure 1 Structure of HCV full-length and sub-genomic clones used in this project. The coding sequence of GFP was inserted in frame
with the NS5A coding sequence of JFH1 cDNA clone between 2394 and 2395 amino acids position (between 417 and 418 amino acids of NS5A
protein). Changes in the nucleotide and amino acid sequences of NS5A gene of HCV-GFP chimera clone are shown. GFP was also inserted at
the similar location of NS5A gene (between 417 and 418 amino acids) in the sub-genomic clone, GND mutant clone and E1-E2 deleted mutant
clone.
Figure 2 Replication of JFH1-GFP full-length RNA and JFH1-
GND-GFP mutant RNA in Huh-7.5 cells after transfection. Huh-
7.5 cells were electroporated with 10 μgo fin vitro transcribed RNA
prepared either from full-length or GND mutant plasmid.
Intracellular expression of GFP in the transfected culture was
examined under a fluorescence microscope. (A) Intracellular GFP
expression in Huh-7.5 cells transfected with JFH1-GFP RNA at 0, 24,
48, 72 and 96 hours. (B) Intracellular expression of GFP in Huh-7.5
cells transfected with JFH1-GND-GFP mutant RNA at 0, 24, 48, 72
and 96 hours. (C) Intracellular GFP expression measured by flow
cytometry in the Huh-7.5 cells transfected with JFH1-GFP RNA after
72 hours. (D): Intracellular GFP expression measured by flow
cytometry in the transfected cells of JFH1-GND-GFP mutant RNA
after 72 hours.
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was undetectable in Huh-7.5 cells transfected with GND
m u t a n tR N A .T h ep r e s e n c eo fn e g a t i v es t r a n dH C V
RNA in the full-length transfected cells confirmed active
replication of virus in the culture. Based on the results
of these experiments we conclude that the chimeric
JFH1-GFP clone is replication competent.
To examine infectious virus particle production from
cells transfected with JFH1-GFP chimera RNA, an infec-
tivity assay was performed. Culture supernatants were
collected from transfected cells, clarified by centrifuga-
tion and inoculated to Huh-7.5 cells. The infectivity of
HCV was confirmed by direct examination of infected
cells under a fluorescence microscope and HCV RNA
levels were measured by real-time RT-PCR assay. Infec-
tivity of culture supernatants from cells transfected with
full-length and E1-E2 deleted mutant clone was deter-
mined by measuring intracellular GFP expression. There
was an increase in the number of GFP positive cells
after 24, 48 and 72 hours suggesting the replication of
HCV RNA after natural infection (Fig. 4A). No GFP
expression was observed in Huh-7.5 cells infected with
supernatants derived from cells transfected with E1-E2
deleted mutant HCV RNA (Fig. 4B). To confirm that
the expression of HCV in the infected cells is associated
with the increase in viral RNA, the titer of HCV positive
strand RNA was measured using a real-time RT-PCR.
The level of HCV RNA in the infected cell cultures was
increased from 24 to 72 hours suggesting the replication
of HCV-RNA genome in the infected culture (Fig. 4C).
Thus, JFH1-GFP-tagged HCV RNA genome is able to
replicate in Huh-7.5 cells after transfection and gener-
ates an infectious virus.
High-level replication of GFP labeled sub-genomic RNA of
HCV 2a clone
Since the JFH1 2a clone replicates to a high level in a
cell culture without adaptive mutations, we attempted to
develop stable replication competent Huh-7 cells con-
taining GFP labeled sub-genomic HCV RNA. The avail-
ability of these cell lines allowed us to reliably quantify
the antiviral effect of IFN-a. A chimeric clone combin-
ing GFP and sub-genomic clone was prepared. As a
control, GND mutant (pSGR-GND-GFP) for the repli-
con clone was also prepared. The full-cycle replication
of pSGR-GFP RNA and unmodified pSGR-RNA in
Huh-7 cells were compared for their ability to form cell
colonies when cultured in the presence of a medium
containing G-418 (500 μg/ml). In this assay, the cells
supporting HCV RNA replication survived G-418 drug
selection and formed cell colonies. No noticeable differ-
ences in the efficiency of replication of the sub-genomic
RNA with or without GFP insertion in the NS5A region
were observed based on the number of G-418 resistant
Figure 3 Detection of positive and negative strand HCV RNA in
the transfected Huh 7.5 cells by RPA. Huh-7.5 cells were
transfected with 10 μgo fin vitro transcribed full-length JFH1-GFP
and JFH1-GND-GFP mutant HCV RNA by electroporation. Total RNA
was isolated from the RNA transfected cell culture at 0, 24, 48, 72
and 96 hours post-transfection. For the detection of positive strand
HCV RNA, total cellular RNA was hybridized with a negative strand
RNA probe targeted to the highly conserved 5’UTR region and then
RPA experiment was performed. For the detection of negative
strand RNA, total cellular RNA was hybridized with a positive sense
RNA probe targeted to the 5’UTR region and then RPA was
performed. (A) Intracellular HCV positive strand RNA in the Huh-7.5
cells transfected with full-length and mutant JFH1-GFP RNA at 0, 24,
48, 72 and 96 hours post-transfection. GAPDH mRNA levels was
used as a loading control. (B) Replicative negative strand HCV-RNA
in Huh-7.5 cells transfected with JFH1-GFP and JFH1-GND-GFP
mutant RNA. The bottom panel shows the intracellular GAPDH
mRNA level indicating that equal amounts of RNA were loaded in
each well in the RPA assay.
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Page 7 of 16cell colonies that appeared on the plate (Fig. 5). No
colonies developed in the culture transfected with the
GND mutant sub-genomic HCV RNA. Individual cell
colonies were picked and stable Huh-7 cell lines sup-
porting replication of HCV-GFP sub-genomic RNA
were developed. The absence of stable DNA integration
in these cell lines was confirmed by direct PCR analysis
for neo gene followed by southern blot analysis. High
levels of GFP expression due to replication of sub-geno-
mic HCV 2a clone was seen in sensitive and resistant
Huh-7 clones (Fig. 6A). The expression of HCV-GFP
chimera protein was seen exclusively in the cytoplasm
in the majority of Huh-7 cells in the culture. These cell
lines have maintained stable GFP expression over more
than one year when cultured in a growth medium sup-
plemented with G-418 (500 μg/ml). Two types of stable
replicon cell lines were prepared using Huh-7 cells with
or without functional Jak-Stat pathway. Stable HCV-
GFP replicon cell lines prepared using IFN sensitive (S-
Huh-7) cells were named as S3-GFP and S10-GFP repli-
cons. Replicon cell lines, also prepared using IFN resis-
tant Huh-7 cell lines (R-Huh-7), were named as R4-GFP
and R8-GFP replicons. The level of GFP expression in
the IFN sensitive and resistant replicon Huh-7 cell lines
was quantitatively determined by flow analysis. The
results of these experiments suggest that more than 80%
of replicon cells express GFP (Fig. 6B).
Antiviral activity of IFN-a against full-length HCV 2a is
blocked in Huh-7 cell clone (R-Huh 7) with a defective
Jak-Stat pathway
The development of JFH1-GFP chimera using the HCV
2a clone allowed us to quantify the antiviral properties
of IFN-a in Huh-7 cells. One important predictive fac-
tor associated with IFN response is the viral genotype. It
has been reported by a number of investigators that the
sustained virological response in patients infected with
HCV genotype 2 is much higher than in patients
Figure 4 Infectivity of virus particles produced from Huh-7.5 cells transfected with JFH1-GFP chimeric genome and JFH1-ΔE-E2-GFP
deleted mutant clone. Huh-7.5 cells were transfected with 20 μgo fin vitro transcribed HCV RNA. After 72 hours, cells along with supernatants
were harvested. Four rounds of freezing and thawing using dry ice lysed the cells. Cell free supernatants were collected by centrifugation at
3500 rpm using a tabletop centrifuge. The titer of HCV in the supernatant was determined by real-time RT-PCR. The TCID50 of infectious
supernatant was determined by using 10-serial dilution of the virus stock. (A) Intracellular GFP expression in the infected Huh-7.5 cells at 0, 24,
48, 72 and 96 h using MOI of 10 or TCID50 (i.e 10
5 virus particle/ml). At different time intervals, cells were taken out from the culture, fixed and
GFP examined under a fluorescence microscope. Increased expression of GFP in the infected culture was seen. (B) Intracellular GFP expression in
Huh-7.5 cells infected using supernatants of E1-E2 deleted mutant construct. No GFP signal was seen in cells infected using culture supernatants
of E1-E2 deleted clone. (C) Real-time RT-PCR was used to quantify the HCV RNA level in the infected cells using a primer targeted to the HCV
5’UTR region. HCV RNA titer in the infected cultures was increased with time suggesting that replication of HCV genome in the infected culture.
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Page 8 of 16infected with genotype 1 virus. We conducted experi-
ments to determine whether the replication of an HCV
2a strain could be inhibited in liver cells (R-Huh-7) hav-
ing a defective Jak-Stat pathway. Both S-Huh-7 and R-
Huh-7 cells were transfected individually with full-
length JFH1-GFP RNA and then treated with an
increasing concentration of IFN-a. We first determined
that both S-Huh-7 and R-Huh-7 cells developed in our
laboratory supported HCV 2a replication and infection.
The ability of IFN-a to inhibit full-length HCV 2a repli-
cation in these two different Huh-7 clones was exam-
ined in a kinetic study at 24 to 96 hours. Results shown
in the upper panel of Fig. 7A suggest that GFP expres-
sion can be efficiently inhibited in S-Huh-7 cell clones.
There was no reduction in GFP expression in the R-
Huh-7 cell clones with a defective Jak-Stat pathway at
all time points (lower panel of Fig. 7A). The antiviral
effect of IFN-a against HCV 2a in these two cell clones
(S-Huh-7 and R-Huh-7) was also quantified by flow
cytometric analysis. We found a time dependent effect
of IFN-a on HCV 2a replication in S-Huh-7 cells and
the number of GFP positive cells was decreased from
4.2% to 0.2% as compared to resistant Huh-7 cell line
(Fig. 7B). To verify that the inhibition of GFP is also
associated with the reduction of viral RNA in the inter-
feron treated cells, RNA extracts were assayed for HCV
RNA by RPA assay using a probe targeted to the 5’
UTR region of HCV genome. We found that interferon
treatment decreased HCV RNA levels in S-Huh-7 clones
and the levels of HCV RNA remained unchanged after
interferon treatment in the resistant clone. (Fig. 7C).
The ability of IFN-a to stop viral RNA replication in
the infected cells was also examined using these two
Huh-7 cell clones. IFN-a treatment efficiently inhibited
HCV replication as measured by GFP expression in S-
Huh-7 cells within 24 hours (Fig 8A). However, antiviral
activity of IFN-a against the full-length HCV 2a replica-
tion was prevented in R-Huh-7 cells with the defective
Jak-Stat pathway (Fig. 8B). The results of these experi-
ments indicate that antiviral activity of IFN-a to inhibit
replication of full-length HCV 2a clone was prevented
in R-Huh-7 clone with defective Jak-Stat pathway.
Antiviral activity of IFN-a is impaired against HCV 2a sub-
genomic clone in Huh-7 cell clone with a defective Jak-
Stat pathway
The role of the Jak-Stat pathway in the IFN-a response
to HCV 2a was also studied using an IFN sensitive (S3-
GFP) and IFN resistant (R4-GFP) stable Huh-7 cell line
that replicates sub-genomic RNA. Replication of HCV
2a sub-genomic RNA in the S3-GFP after IFN-a treat-
ment was studied by measuring the intracellular GFP
expression directly under a fluorescence microscope. It
was found that GFP expression in the stable cell line
(S3-GFP) diminished over time (Fig 9A). Where as no
reduction of the HCV-GFP signal in R4-GFP replicon
was observed even when treated with a similar concen-
tration of IFN-a for an extended period. To quantify
the IFN antiviral effect intracellular GFP expression was
analyzed by flow analysis. The GFP peak disappeared
after IFN treatment only in the S3-GFP replicon cell
line (53% to 2%). The percentage of GFP positive cells
did not decrease (58% to 55%) when similar experiments
were carried out using R4-GFP cells (Fig. 9B). To
Figure 5 Replication of unmodified sub-genomic HCV 2a RNA clone and GFP labeled sub-genomic HCV 2a chimera in Huh-7 cells.
Huh-7 cells were transfected with 10 μg of in vitro transcribed RNA by the electroporation method and then cultured in the medium
containing G-418 (500 μg/ml). After 4-weeks, G-418 resistant cell colonies were stained with Giemsa Stain (Sigma Chemical). Both the unmodified
(pSGR) and GFP tagged sub-genomic clone (pSGR-GFP) replicated at equal efficiencies based on the development of number of G-418 resistant
Huh7 cell colonies. No G-418 resistant colonies were present in Huh-7 cells with GND mutant sub-genomic RNA with GFP (pSGR-GND-GFP).
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Page 9 of 16correlate the results of GFP expression, intracellular
HCV RNA after IFN-a treatment was also measured by
RPA. The results of RPA assays demonstrate that HCV
RNA replication is not inhibited by IFN-a treatment in
the R4-GFP replicon cell line (Fig. 9C). The level of
HCV RNA was also quantified by real-time PCR in
these two cell lines after IFN treatment. IFN-a treat-
ment inhibited the HCV RNA level in a dose dependent
manner in S3-GFP but the HCV RNA level remained
t h es a m ei nt h eR 4 - G F Pr e p l i c o n .T h e r ew a sas i g n i f i -
cant difference in the level of HCV RNA between the
IFN sensitive replicon and resistant replicon after IFN
treatment measured by real-time PCR (Fig. 9D). These
results suggest that replication of HCV 2a full-length as
well as sub-genomic RNA can not be inhibited by IFN-
a in R-Huh-7 cells with a defective Jak-Stat pathway.
HCV infection and replication did not alter the state of
Jak-Stat pathway in S-Huh-7 and R-Huh-7 cell clones
Experiments were carried out to examine whether infec-
tion or replication of HCV in both S-Huh-7 and R-
Huh-7 cells could have any impact on the IFN-a
induced Jak-Stat signaling. The levels of pStat1 and
pStat2 proteins in the lysates of S-Huh-7 and R-Huh-7
cells after 96 hours of HCV infection were examined by
western blot analysis. Results shown in Fig. 10A and
10B clearly show that IFN-a treatment induced pStat1
and pStat2 protein in the infected as well uninfected S-
Huh-7 only. However, pStat1 or pStat2 protein was not
Figure 6 Preparation of stable replicon cell line replicating HCV 2a sub-genomic RNA. Interferon sensitive (S3-GFP) and interferon resistant
(R4-GFP) Huh-7 cells were transfected with pSGR-GFP replicon RNA and then selected with G-418 (500 μg/ml). Single G-418 resistant cell clones
were picked and stable cell lines were generated. (A) Intracellular GFP expression in S3-GFP and R4-GFP stable replicon cell lines. (B)
Quantification of GFP expression in these IFN-sensitive (S3-GFP) and resistant (R4-GFP) cells was performed flow analysis. Approximately 81% of
S3-GFP and 84% of R4-GFP cells in the culture showed intracellular GFP expression. High-level expression of HCV-GFP was seen in both cell lines
suggesting that both the sensitive and resistant Huh-7 clones support high level HCV replication.
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feron treatment. These results were confirmed by a co-
localization of pStat1 protein in the GFP labeled repli-
con cells after IFN-treatment. We show that pStat1 is
induced only in the sensitive replicon (S3-GFP) and
localizes to the nucleus. The nuclear translocation of
pStat1 is correlated with a decrease in GFP expression
after IFN-a at 72 hours in the S-Huh-7 cells only (Fig.
10C). The pStat1 protein was undetectable in R4-GFP
cells after IFN-a treatment. To examine if the effect of
HCV infection or replication in both S-Huh-7 and R-
Huh-7 could alter the overall Jak-Stat signaling, the
ISRE-luciferase promoter activity was examined by a
transient transfection assay. Interferon induced activity
of ISRE-luciferase did not change significantly in R-
Huh-7 cells after HCV infection (Fig. 10D).
Discussion
The JFH1 full-length cDNA clone of HCV 2a strain was
isolated from a chronically infected Japanese patient by
Wakita and his coworkers [14]. JFH1 derived clones
replicate at a greater efficiency than all other HCV
strains, making it the system of choice for biochemical
studies that address HCV replication mechanisms and
virus host interactions. The replication of full-length
virus in cell culture is assessed by the detection of viral
R N Ab yu s i n gah i g h l ys e n s i t i v eR T - P C Rm e t h o d .V i r a l
proteins were detected by western blot analysis, ELISA
or immunocytochemistry. These methods are highly
specific and accurately determine the replication kinetics
but are complex and time consuming. To overcome
these difficulties, we prepared a chimeric clone of JFH1
by inserting the coding sequence of EGFP-N1 in the
NS5A coding sequences. We noticed that a high-level
Figure 7 Antiviral effect IFN-a on the replication of JFH1-GFP RNA using S-Huh-7 and R-Huh-7 cells in culture. (A) S-Huh-7 and R-Huh-7
cells were transfected with full-length JFH1-GFP RNA and next day the cultures were treated with IFN-a (1000 IU/ml). Intracellular GFP
expression was measured after 24, 48, 72 and 96 hours of post-transfection. Upper panel shows the intracellular GFP expression after IFN-a
treatment in S-Huh-7 cells. Bottom panel shows the intracellular GFP expression in R-Huh-7 cells after IFN-a treatment (B) Quantification of
antiviral effect of IFN-a (1000 IU/ml) between these two cell lines by flow analysis after 72 hours of post-transfection. In the S-Huh-7 cell line the
number of GFP positive cells were decreased from 4.2% to 0.2% after IFN-a treatment. There is no decrease in the number of GFP positive cells
after IFN-a treatment in the transfected R-Huh-7 cells. The upper and lower left panel shows the untransfected cells as mock. (C) Intracellular
HCV mRNA levels in the IFN treated cells measured by RPA. The experiments were carried out same way as described in the panel A; except
that the RPA analysis was performed using the total RNA isolated from the transfected cells at different time points. Upper panel shows the HCV
RNA level in the transfected S-Huh-7 cells after IFN-a treatment. Bottom panel shows the HCV RNA levels in the transfected R-Huh-7 cells after
IFN-a treatment.
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7.5 cells 24 h after transfection. The expression of GFP
in the transfected cells is an indication of active replica-
tion of the HCV genome since no GFP expression was
detected in cells transfected with a GND mutant RNA.
Replication of JFH1-GFP RNA in the transfected cell is
supported by the results of detection of positive and
negative strand RNA. We also showed that the trans-
fected cells produced infectious virus particles. The
infection can be transferred to naïve Huh-7 cells in a
culture. The expression of GFP protein and viral RNA
increased over time in the infected culture suggest that
the replication of HCV occurred over time after natural
infection. We also prepared a JFH1 sub-genomic clone
with GFP as a fusion protein. Multiple stable replicon
cell lines containing the GFP chimeric clone and neo-
mycin selection marker were prepared in Huh-7 cells.
Replication of sub-genomic clone of HCV 2a in the
Huh-7 cells was stable. High-level expression and repli-
cation of HCV sub-genomic RNA was observed in the
cells for over one year, and can be assayed by flow ana-
lysis. Stable cell lines replicating HCV sub-genomic
Figure 8 Antiviral effect of IFN-a against HCV replication in the infected Huh-7 cells in culture. S-Huh-7 and R-Huh-7 cells were seeded at
density of 1 × 10
4 cell per well in a chamber slide. The next day cultures were infected with infectious HCV GFP virus at the TCID50 (1 × 10
5
virus particles/ml) or MOI of 10 using the standard protocol described in the material and method section. After 24 hours cultures were treated
with IFN-a (1000 IU/ml). (A) Intracellular GFP expression in the infected S-Huh-7 cells in culture at 24, 48, 72 and 96 hours of post-infection in
the presence and absence of IFN-a. The results show that HCV RNA replication in the infected cells can be inhibited over time by treatment
with alpha interferon in S-Huh-7 cells. (B) Intracellular GFP expression in the infected R-Huh-7 cells in culture at 24, 48, 72 and 96 hours of post-
infection in the presence and absence of IFN-a. The results suggest that HCV RNA replication remain resistant to IFN-a treatment at all time
points in infected R-Huh-7 cells with a defective Jak-Stat pathway.
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resistant Huh-7 cells (R-Huh7). We now clearly showed
that replication of HCV-GFP chimera cannot be inhib-
ited by IFN-a in Huh-7 cells with defective Jak-Stat
pathway.
The availability of a full-length GFP clone and stable
replicon cell lines have allowed us to examine the anti-
viral mechanisms of IFN-a against HCV 2a strain in cell
culture. There are reports suggesting that the effective-
ness of the IFN response depends on the viral genotype.
We performed a study to examine differences in the
level of IFN response of HCV using the HCV 2a replica-
tion system. Previously, we have demonstrated that both
the HCV 1a and HCV 1b strain can be efficiently
inhibited by IFN-a within 72 h in a concentration
dependent manner [18,19]. In this study we provide evi-
dence suggesting that interferon alpha treatment inhib-
ited HCV RNA replication of full-length as well as
replication of HCV sub-genomic RNA in a dose depen-
dent manner. These results are also consistent with a
previous report suggesting that IFN inhibits replication
of HCV 2a and HCV 1b strain in a dose dependent
manner [29]. The role of virus and the Jak-Stat pathway
of host cell in the IFN response using HCV 2a cell cul-
ture system were examined. We showed here that IFN-
a treatment induced phosphorylation of Stat1 and Stat2
proteins in the infected S-Huh-7 cells and successfully
inhibited HCV RNA replication. However, we could not
Figure 9 Antiviral effect of IFN-a using stable cell lines replicating GFP labeled sub-genomic RNA of HCV 2a. S3-GFP and R4-GFP were
treated with IFN-a from 10 to 1000 IU/ml. (A) Upper panel shows the antiviral effect of IFN-a against HCV 2a sub-genomic RNA replication in
S3-GFP cells. There was a dose dependent decrease in the GFP expression in the S3-GFP cells with increasing concentration of IFN-a. Lower
panel shows no effect of GFP expression in R4-GFP cells. (B) The GFP fluorescence was quantitatively measured by flow cytometry analysis after
IFN-a treatment (1000 IU/ml) for 72 hours using S3-GFP and R4-GFP cells. A significant reduction in the number of GFP positive S3-GFP cells
(53% to 2%) was seen after IFN treatment. The number of GFP-positive cells did not decrease when treated with interferon (58% to 55%) using
R4-GFP cells. (C) RPA shows the intracellular HCV RNA level in the S3-GFP and R4-GFP after IFN-a treatment. Left panel shows HCV RNA levels in
S3-GFP after IFN-a treatment at 72 hours. Right panel shows the HCV RNA level in R4-GFP after IFN-a treatment at 72 hours. There is a gradual
reduction of HCV mRNA level in the S3-GFP replicon cells compared to the R4-GFP cells. (D) Shows the quantification of HCV RNA levels in the
S3-GFP and R4-GFP after IFN-a treatment at 72 hours by real-time RT-PCR. In both the cells the HCV RNA level was detected up to a level of
titer of log 7 GE/μg of total RNA. The HCV RNA levels reduced significantly after IFN-a treatment at 1000 IU/ml in the S3-GFP replicon cells.
There was no decrease in the HCV RNA level in R4-GFP cells after IFN-a treatment.
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infected R-Huh-7 cells after IFN-a treatment. The IFN-
a induced Jak-Stat mediated ISRE-luciferase activity of
R-Huh-7 cells did not change significantly with or with-
out HCV infection. We showed here that IFN-a is not
able to inhibit the replication of full-length as well as
sub-genomic HCV 2a virus in R-Huh-7 cell clone sug-
gesting a dominant role of cellular Jak-Stat pathway in
the response to the interferon treatment [22].
The overall sustained virological response of patients
infected with HCV genotype 2 and 3 is about 80% as
compared to only 50% in the case of chronic HCV
patients that are infected with HCV genotype 1 strain
[3]. The mechanisms that determine the response at the
genotype level are not clear. There has been a report
suggesting that the IFN treatment response alters two
phases of viral replication kinetics [30]. The first phase
is the dose dependent reduction of HCV RNA levels in
the liver within the first 24 hours after treatment. The
second phase of IFN-induced decline of HCV RNA
occurs over weeks to months. The first phase viral
decay may be due to the direct action of interferon on
HCV production and the second phase may be due to
death of infected cells. In our analysis, we have found
that there is no difference in the efficacy of IFN upon
replication of HCV 2a and HCV genotype 1b viruses. It
will be important to determine if there are differences in
death of hepatocytes when they are infected with HCV
Figure 10 IFN-a induced Jak-Stat signaling in both S-Huh-7 and R-Huh-7 cells after HCV 2a infection. (A) Both S-Huh-7 and R-Huh-7 cells
were infected with JFH1-GFP chimera virus for 96 hours. The phosphorylation of Stat1 protein in the infected cultures after 30 minutes of IFN-a
treatment (1000 IU/ml) was determined by western blot analysis. Equal amounts of proteins were used in the blot to assay for total Stat1 and
beta-actin levels. (B) IFN-a induced pStat2 protein in S-Huh-7 and R-Huh-7 cells with or without HCV 2a infection. The experiment was carried
out as described in panel A. Equal amounts of proteins were used in the blot to assay for total Stat2 and beta-actin levels. (C) Demonstrates IFN-
a induced nuclear localization of pStat1 in the S3-GFP and R4-GFP stable replicon cells at 24 and 72 hours by immunofluorescence microscopy
using anti-mouse pStat1 (1:1000 dilution) and Alexaflour labeled anti-mouse secondary antibody (1:2000 dilution). The pStat1 protein was
detected in the nucleus of S3-GFP replicon cells only at 24 and 72 hours after IFN-a treatment. The pStat1 translocation is associated with
negative GFP expression after 72 hours of IFN-a treatment only in S3-GFP cells. (D) IFN-a induced ISRE-luciferase activity in S-Huh-7 and R-Huh-7
cells after HCV 2a infection. Both S-Huh-7 and R-Huh-7 cells were were infected with full-length HCV. After 72 hours, infected cells were
transfected with μgm of pISRE-luciferase plasmid. After 24 hours, ISRE-luciferase activity in the cell lysates were measured in the presence and
absence of IFN-a(1 IU/ml) treatment for 24 hours. The values were calculated as fold increase with respect to untreated cells.
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Page 14 of 16genotype 1 and HCV 2a virus. Our study provides evi-
dence suggesting that cells with defective Jak-Stat path-
way of IFN-signaling can prevent the antiviral response
after IFN-a treatment. This conclusion supports results
from previous studies using HCV cell cultures [22,31] as
well as by a recent multicenter study using clinical sam-
ples from HALT-C trial suggesting that response to IFN
therapy is dependent upon the host genetic polymorph-
isms of Tyk2 in the liver cells [32]. In summary, results
of this investigation support the importance of host cell
factors in the mechanisms of IFN-resistance in chronic
HCV infection. The development of IFN-sensitive and
IFN-resistant GFP tagged HCV 2a replicon cell lines
will allow us to further understand the mechanisms of
resistance against HCV in tissue culture. In particular,
GFP labeled IFN-resistant replicon cells should be very
useful to develop alternative antiviral strategies to over-
come IFN resistance against HCV.
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